Verrica Pharmaceuticals Inc.
$6.38
▼
-0.36%
2026-04-21 10:10:00
www.verrica.com
NCM: VRCA
Explore Verrica Pharmaceuticals Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$109.6 M
Current Price
$6.38
52W High / Low
$9.82 / $3.28
Stock P/E
—
Book Value
$1.44
Dividend Yield
—
ROCE
-38.9%
ROE
-2.4%
Face Value
—
EPS
$-1.68
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
76
Beta
1.43
Debt / Equity
6.59
Current Ratio
2.59
Quick Ratio
2.45
Forward P/E
-3
Price / Sales
2.47
Enterprise Value
$59.27 M
EV / EBITDA
-5.17
EV / Revenue
1.67
Rating
None
Target Price
$16.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Immix Biopharma, Inc. | $10.09 | — | $548.68 M | — | -31.62% | -55% | $11.61 / $1.57 | $1.77 |
| 2. | Cogent Biosciences, Inc. | $37 | — | $6.05 B | — | -38.16% | -73.7% | $43.73 / $4.12 | $3.4 |
| 3. | Aligos Therapeutics, Inc. | $6.51 | — | $41.33 M | — | -130.74% | -1.97% | $13.69 / $4.2 | $8.67 |
| 4. | Rezolute, Inc. | $3.37 | — | $322.5 M | — | -48.84% | -74.02% | $11.46 / $1.07 | $1.23 |
| 5. | Fractyl Health, Inc. | $0.58 | — | $90.33 M | — | -93.93% | -7.44% | $3.03 / $0.38 | $0.06 |
| 6. | Liminatus Pharma, Inc. | $0.22 | — | $9.83 M | — | 30.51% | — | $33.66 / $0.16 | $-0.06 |
| 7. | CRISPR Therapeutics AG | $57.69 | — | $5.56 B | — | -31.41% | -30.18% | $78.48 / $33.03 | $20.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 5.09 M | 14.34 M | 12.7 M | 3.44 M | 0.34 M | — |
| Operating Profit | -6.95 M | 1.63 M | 1.51 M | -8.13 M | -11.33 M | — |
| Net Profit | -8.07 M | -0.27 M | 0.2 M | -9.74 M | -16.2 M | — |
| EPS in Rs | -0.47 | -0.02 | 0.01 | -0.57 | -0.94 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 35.58 M | 7.57 M | 5.12 M | 9.03 M |
| Operating Profit | -11.94 M | -65.84 M | -63.22 M | -21.3 M |
| Net Profit | -17.89 M | -76.58 M | -67 M | -24.49 M |
| EPS in Rs | -1.04 | -4.46 | -3.9 | -1.43 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 47.13 M | 54.13 M | 81.6 M | 44.72 M |
| Total Liabilities | 22.39 M | 63.99 M | 61.83 M | 4.69 M |
| Equity | 24.74 M | -9.86 M | 19.76 M | 40.03 M |
| Current Assets | 42.54 M | 51.18 M | 77.53 M | 39.12 M |
| Current Liabilities | 16.44 M | 29.01 M | 17.02 M | 3.46 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -17.63 M | -60.93 M | -38.58 M | -18.65 M |
| Investing CF | 0 M | -0.02 M | -0.36 M | 54.04 M |
| Financing CF | 1.45 M | 37.73 M | 74.21 M | -16.87 M |
| Free CF | -17.63 M | -60.95 M | -38.94 M | -18.95 M |
| Capex | — | -0.03 M | -0.36 M | -0.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 47.66% | -43.27% | — | — |
| Earnings Growth % | -14.31% | -173.59% | — | — |
| Profit Margin % | -1012.15% | -1307.47% | -271.11% | — |
| Operating Margin % | -870.16% | -1233.84% | -235.78% | — |
| Gross Margin % | 63.79% | 85.44% | 91.97% | — |
| EBITDA Margin % | -870.98% | -1213.84% | -239.12% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-07-25 | 1:0.1 |